Neurocrine Biosciences’s Licensing and Collaboration Agreement With Xenon Pharmaceuticals

Ambrogio Visconti

Cooley LLP advised Neurocrine Biosciences on its licensing and collaboration agreement with Xenon Pharmaceuticals to develop first-in-class treatments for epilepsy. Neurocrine will pay Xenon $50 million…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now